Marshall Wace
CMPX icon

Marshall Wace’s Compass Therapeutics CMPX Stock Holding History

Marshall Wace’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,263,647
Closed -$6.79M – 3259
2025
Q4 		$6.79M Buy
+1,263,647
New +$5.84M 0.01% 1022
2023
Q2 		– Sell
-65,177
Closed -$213K – 2527
2023
Q1 		$213K Buy
65,177
+36,881
+130% +$145K ﹤0.01% 2400
2022
Q4 		$142K Sell
28,296
-23,520
-45% -$93.8K ﹤0.01% 2747
2022
Q3 		$117K Buy
51,816
+28,089
+118% +$77.8K ﹤0.01% 3169
2022
Q2 		$63K Buy
+23,727
New +$51.5K ﹤0.01% 3315

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace's CMPX Position: Q1 2026 in Review

Marshall Wace sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 1,263,647 shares — an estimated $6.79M sold.

Marshall Wace first reported a position in CMPX in Q2 2022 and held it in 5 quarters. The position peaked at $6.79M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Marshall Wace reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 1,263,647 Compass Therapeutics shares in Q1 2026, an estimated $6.79M.
  • Marshall Wace first reported a position in Compass Therapeutics in Q2 2022 and held it in 5 quarters.
  • Marshall Wace's Compass Therapeutics position peaked at $6.79M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.